Mianserine Zentiva

Mianserin, the active ingredient in Mianserine Zentiva, is a tetracyclic antidepressant presented as an oral tablet for oral administration. It is indicated for the treatment of major depressive disorder in adult patients, helping to alleviate depressive symptoms through modulation of neurotransmitter activity. The medication is formulated to ensure consistent bioavailability and is manufactured under strict quality standards.

GNH USA supplies Mianserine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for this prescription medication. Our logistics network ensures timely delivery while complying with local import regulations and safety requirements.

Mianserin is a tetracyclic antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms in adults - Depressive disorder: improves mood, motivation and overall functioning - Treatment‑resistant depression: may be considered as an adjunct when first‑line agents are insufficient

Mianserin may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Drowsiness - Dry mouth - Weight gain - Constipation

Serious or Rare Side Effects: - Agranulocytosis - Seizures - Severe hypotension

When prescribing Mianserin, clinicians should consider several safety measures.

- Monitor blood counts: baseline and periodic CBC due to risk of agranulocytosis. - Assess cardiovascular status: caution in patients with hypotension. - Evaluate hepatic function: use with caution in liver impairment. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at room temperature: keep in original container, protect from moisture and light.

Mianserin can interact with various medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants: additive sedation. - Serotonergic agents: potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance hypotensive effect. - Anticholinergic drugs: increased anticholinergic burden. - Alcohol: may increase drowsiness.